| Field | Specification |
|---|---|
| Target | |
| Alternative names | Autoantigen PM/Scl 2; Exosc10; Exosome component 10; EXOSX_HUMAN; P100 polymyositis scleroderma overlap syndrome associated autoantigen; P100 polymyositis-scleroderma overlap syndrome-associated autoantigen; p2; p3; p4; PM Scl; PM/Scl 100; PM/Scl-100; PMSCL; PMSCL2; Polymyositis/scleroderma autoantigen 100 kDa; Polymyositis/scleroderma autoantigen 2 100 kDa; Polymyositis/scleroderma autoantigen 2; RRP6; Rrp6p |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Recombinant Human Exosome component 10 protein (587-762AA) |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This polyclonal anti-EXOSC10 antibody raised in Rabbit, tested in ELISA, IHC. Designed to detect EXOSC10 in Human for immunology research.
Key elements and design rationale
- Immunogen: Recombinant Human Exosome component 10 protein (587-762AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
Biological background
EXOSC10 (also: Autoantigen PM/Scl 2, Exosc10, Exosome component 10, EXOSX_HUMAN, P100 polymyositis scleroderma overlap syndrome associated autoantigen, P100 polymyositis-scleroderma overlap syndrome-associated autoantigen, p2, p3, p4, PM Scl, PM/Scl 100, PM/Scl-100, PMSCL, PMSCL2, Polymyositis/scleroderma autoantigen 100 kDa, Polymyositis/scleroderma autoantigen 2 100 kDa, Polymyositis/scleroderma autoantigen 2, RRP6, Rrp6p) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current EXOSC10 annotation relevant to immunology.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
- IHC: Tissue expression in FFPE/frozen sections; optimize antigen retrieval.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
EXOSC10 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects EXOSC10 in ELISA, IHC applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA, IHC. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Non-conjugated IgG; requires anti-rabbit-IgG secondary conjugated to your preferred reporter (HRP, AP, fluorophore, or biotin).
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing EXOSC10; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
